Скачать с ютуб NETTER-1: Radioactive Octreotide Effective in Metastatic Neuroendocrine Tumors в хорошем качестве

NETTER-1: Radioactive Octreotide Effective in Metastatic Neuroendocrine Tumors

Jonathan R. Strosberg, MD, medical oncologist, Department of Gastrointestinal Oncology at the Moffitt Cancer Center talks about the phase III NETTER-1 trial for midgut neuroendocrine tumors (NETs). The NETTER-1 trial compared the efficacy of 177-Lu-Dotatate (Lutathera) with octreotide (Sandostatin LAR) in patients with advanced progressive disease. Results showed that the median progression-free survival (PFS), the trial's primary endpoint, improved by 80% (HR, .21). The median time-to-progression with high-dose octreotide was 8.7 months and not yet reached in the 177-Lu-Dotatate arm at a median follow-up of 18 months. Other endpoints were also favorable towards the targeted radioactive treatment arm.